Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Fried v. Stiefel Laboratories, Inc. et al
Case Number:
1:11-cv-20853
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 23, 2014
Stiefel Escapes Bid For New Trial In $2M Securities Suit
A Florida federal judge on Monday denied a former Stiefel Laboratories Inc. executive's motion for a new trial after a jury found the company and its ex-CEO did not commit securities fraud by persuading him to sell back his stock at artificially low prices ahead of its 2009 acquisition by GlaxoSmithKline PLC.
-
December 19, 2013
How They Won It: Greenberg Wins Stiefel Securities Verdict
Greenberg Traurig LLP attorneys relied on flexibility in rebuffing an investor's $2.5 million suit against Stiefel Laboratories Inc. and its former CEO with a defense that focused on providing context and poking holes in the plaintiff's storyline — and could prove significant for related pending cases.
-
November 08, 2013
Stiefel Labs, Ex-CEO Cleared Of $2M Securities Fraud Claim
A federal jury in Miami on Wednesday found that Stiefel Laboratories Inc. and former chief executive Charles Stiefel did not commit securities fraud or breach fiduciary duty in connection with a former executive's sale of company stock ahead of Stiefel's 2009 acquisition by GlaxoSmithKline PLC.